15
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Cytotoxic CD8 + T lymphocytes expressing ALS-causing SOD1 mutant selectively trigger death of spinal motoneurons

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Significance

          CD8 + T lymphocytes, which are typically devoted to eliminate malignant and infected cells, have been described in the central nervous system (CNS) of patients and mice with amyotrophic lateral sclerosis (ALS). However, their role in ALS pathogenesis has yet to be unraveled. Here, we show that ablation of CD8 + T cells in ALS mice increased the number of surviving motoneurons. CD8 + T cells expressing the ALS-causing superoxide dismutase-1 mutant protein recognize and selectively kill motoneurons in vitro. To exert their cytotoxic function, mutant CD8 + T cells required presentation of the antigen-MHC-I complex at the surface of the motoneurons. Analysis of T cell receptor diversity supports the evidence that self-reactive CD8 + T lymphocytes infiltrate the CNS of ALS mice to exert cytotoxic function.

          Abstract

          Adaptive immune response is part of the dynamic changes that accompany motoneuron loss in amyotrophic lateral sclerosis (ALS). CD4 + T cells that regulate a protective immunity during the neurodegenerative process have received the most attention. CD8 + T cells are also observed in the spinal cord of patients and ALS mice although their contribution to the disease still remains elusive. Here, we found that activated CD8 + T lymphocytes infiltrate the central nervous system (CNS) of a mouse model of ALS at the symptomatic stage. Selective ablation of CD8 + T cells in mice expressing the ALS-associated superoxide dismutase-1 (SOD1) G93A mutant decreased spinal motoneuron loss. Using motoneuron-CD8 + T cell coculture systems, we found that mutant SOD1-expressing CD8 + T lymphocytes selectively kill motoneurons. This cytotoxicity activity requires the recognition of the peptide-MHC-I complex (where MHC-I represents major histocompatibility complex class I). Measurement of interaction strength by atomic force microscopy-based single-cell force spectroscopy demonstrated a specific MHC-I-dependent interaction between motoneuron and SOD1 G93A CD8 + T cells. Activated mutant SOD1 CD8 + T cells produce interferon-γ, which elicits the expression of the MHC-I complex in motoneurons and exerts their cytotoxic function through Fas and granzyme pathways. In addition, analysis of the clonal diversity of CD8 + T cells in the periphery and CNS of ALS mice identified an antigen-restricted repertoire of their T cell receptor in the CNS. Our results suggest that self-directed immune response takes place during the course of the disease, contributing to the selective elimination of a subset of motoneurons in ALS.

          Related collections

          Most cited references40

          • Record: found
          • Abstract: found
          • Article: not found

          T cell antigen receptor recognition of antigen-presenting molecules.

          The Major Histocompatibility Complex (MHC) locus encodes classical MHC class I and MHC class II molecules and nonclassical MHC-I molecules. The architecture of these molecules is ideally suited to capture and present an array of peptide antigens (Ags). In addition, the CD1 family members and MR1 are MHC class I-like molecules that bind lipid-based Ags and vitamin B precursors, respectively. These Ag-bound molecules are subsequently recognized by T cell antigen receptors (TCRs) expressed on the surface of T lymphocytes. Structural and associated functional studies have been highly informative in providing insight into these interactions, which are crucial to immunity, and how they can lead to aberrant T cell reactivity. Investigators have determined over thirty unique TCR-peptide-MHC-I complex structures and twenty unique TCR-peptide-MHC-II complex structures. These investigations have shown a broad consensus in docking geometry and provided insight into MHC restriction. Structural studies on TCR-mediated recognition of lipid and metabolite Ags have been mostly confined to TCRs from innate-like natural killer T cells and mucosal-associated invariant T cells, respectively. These studies revealed clear differences between TCR-lipid-CD1, TCR-metabolite-MR1, and TCR-peptide-MHC recognition. Accordingly, TCRs show remarkable structural and biological versatility in engaging different classes of Ag that are presented by polymorphic and monomorphic Ag-presenting molecules of the immune system.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            CD4+ T cells support glial neuroprotection, slow disease progression, and modify glial morphology in an animal model of inherited ALS.

            Neuroinflammation, marked by gliosis and infiltrating T cells, is a prominent pathological feature in diverse models of dominantly inherited neurodegenerative diseases. Recent evidence derived from transgenic mice ubiquitously overexpressing mutant Cu(2+)/Zn(2+) superoxide dismutase (mSOD1), a chronic neurodegenerative model of inherited amyotrophic lateral sclerosis (ALS), indicates that glia with either a lack of or reduction in mSOD1 expression enhance motoneuron protection and slow disease progression. However, the contribution of T cells that are present at sites of motoneuron injury in mSOD1 transgenic mice is not known. Here we show that when mSOD1 mice were bred with mice lacking functional T cells or CD4+ T cells, motoneuron disease was accelerated, accompanied by unexpected attenuated morphological markers of gliosis, increased mRNA levels for proinflammatory cytokines and NOX2, and decreased levels of trophic factors and glial glutamate transporters. Bone marrow transplants reconstituted mice with T cells, prolonged survival, suppressed cytotoxicity, and restored glial activation. These results demonstrate for the first time in a model of chronic neurodegeneration that morphological activation of microglia and astroglia does not predict glial function, and that the presence of CD4+ T cells provides supportive neuroprotection by modulating the trophic/cytotoxic balance of glia. These glial/T-cell interactions establish a novel target for therapeutic intervention in ALS and possibly other neurodegenerative diseases.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Endogenous regulatory T lymphocytes ameliorate amyotrophic lateral sclerosis in mice and correlate with disease progression in patients with amyotrophic lateral sclerosis

              Amyotrophic lateral sclerosis is a relentless and devastating adult-onset neurodegenerative disease with no known cure. In mice with amyotrophic lateral sclerosis, CD4+ T lymphocytes and wild-type microglia potentiate protective inflammatory responses and play a principal role in disease pathoprogression. Using this model, we demonstrate that endogenous T lymphocytes, and more specifically regulatory T lymphocytes, are increased at early slowly progressing stages, augmenting interleukin-4 expression and protective M2 microglia, and are decreased when the disease rapidly accelerates, possibly through the loss of FoxP3 expression in the regulatory T lymphocytes. Without ex vivo activation, the passive transfer of wild-type CD4+ T lymphocytes into amyotrophic lateral sclerosis mice lacking functional T lymphocytes lengthened disease duration and prolonged survival. The passive transfer of endogenous regulatory T lymphocytes from early disease stage mutant Cu2+/Zn2+ superoxide dismutase mice into these amyotrophic lateral sclerosis mice, again without ex vivo activation, were substantially more immunotherapeutic sustaining interleukin-4 levels and M2 microglia, and resulting in lengthened disease duration and prolonged survival; the stable disease phase was extended by 88% using mutant Cu2+/Zn2+ superoxide dismutase regulatory T lymphocytes. A potential mechanism for this enhanced life expectancy may be mediated by the augmented secretion of interleukin-4 from mutant Cu2+/Zn2+ superoxide dismutase regulatory T lymphocytes that directly suppressed the toxic properties of microglia; flow cytometric analyses determined that CD4+/CD25+/FoxP3+ T lymphocytes co-expressed interleukin-4 in the same cell. These observations were extended into the amyotrophic lateral sclerosis patient population where patients with more rapidly progressing disease had decreased numbers of regulatory T lymphocytes; the numbers of regulatory T lymphocytes were inversely correlated with disease progression rates. These data suggest a cellular mechanism whereby endogenous regulatory T lymphocytes are immunocompetent and actively contribute to neuroprotection through their interactions with microglia. Furthermore, these data suggest that immunotherapeutic interventions must begin early in the pathogenic process since immune dysfunction occurs at later stages. Thus, the cumulative mouse and human amyotrophic lateral sclerosis data suggest that increasing the levels of regulatory T lymphocytes in patients with amyotrophic lateral sclerosis at early stages in the disease process may be of therapeutic value, and slow the rate of disease progression and stabilize patients for longer periods of time.
                Bookmark

                Author and article information

                Journal
                Proc Natl Acad Sci U S A
                Proc. Natl. Acad. Sci. U.S.A
                pnas
                pnas
                PNAS
                Proceedings of the National Academy of Sciences of the United States of America
                National Academy of Sciences
                0027-8424
                1091-6490
                5 February 2019
                23 January 2019
                23 January 2019
                : 116
                : 6
                : 2312-2317
                Affiliations
                [1] aThe Neuroscience Institute of Montpellier, Inserm UMR1051, University of Montpellier , Saint Eloi Hospital, 34090 Montpellier, France;
                [2] bInserm U1183, Institute for Regenerative Medicine and Biotherapy, University of Montpellier , 34090 Montpellier, France;
                [3] cCharles Coulomb laboratory, L2C, UMR5221, University of Montpellier , CNRS, 34095 Montpellier, France;
                [4] dCentre de Recherche en Transplantation et Immunologie UMR1064, INSERM, Université de Nantes , 44093 Nantes, France;
                [5] eInstitut de Transplantation Urologie Néphrologie (ITUN), University Hospital Centre Nantes , 44093 Nantes, France;
                [6] fLudwig Institute for Cancer Research, Lausanne University , CH 1015 Lausanne, Switzerland;
                [7] gReferral Centre for ALS and Neuromuscular Diseases, La Timone University Hospital, Aix-Marseille University , 13005 Marseille, France;
                [8] hImmunology Laboratory, Assistance Publique–Hôpitaux de Marseille , Conception Hospital, 13005 Marseille, France;
                [9] iInstitute of Biophysics, Biological Research Centre, Hungarian Academy of Sciences , H 6726 Szeged, Hungary;
                [10] jTimone Neuroscience Institute, Aix-Marseille University , 13005 Marseille, France;
                [11] kDepartment of Immunology, Saint Eloi Hospital , 34295 Montpellier, France
                Author notes
                1To whom correspondence should be addressed. Email: cedric.raoul@ 123456inserm.fr .

                Edited by Lawrence Steinman, Stanford University School of Medicine, Stanford, CA, and approved December 20, 2018 (received for review September 14, 2018)

                Author contributions: E.C., C. Salsac, G.E.-C., B.V., N.D., F.S., J.B., D.L., J.H., C.G., T.V., and C.R. designed research; E.C., C. Salsac, G.E.-C., B.V., N.D., M.C., R.C., A.V., C. Soulard, J.K.F., M.L., S.V., J.B., J.H., and C.R. performed research; A.G.V. contributed new reagents/analytic tools; E.C., C. Salsac, G.E.-C., B.V., N.D., M.C., R.C., A.V., C. Soulard, J.K.F., A.B., M.L., S.V., F.S., J.B., D.L., J.H., C.G., T.V., and C.R. analyzed data; and E.C. and C.R. wrote the paper.

                Author information
                http://orcid.org/0000-0001-6113-6938
                Article
                201815961
                10.1073/pnas.1815961116
                6369778
                30674678
                42f87a8a-1e63-458c-8e19-5bd8a66f33ea
                Copyright © 2019 the Author(s). Published by PNAS.

                This open access article is distributed under Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND).

                History
                Page count
                Pages: 6
                Funding
                Funded by: Institut National de la Santé et de la Recherche Médicale (Inserm) 501100001677
                Award ID: Recurrent
                Award Recipient : Emmanuelle Coque Award Recipient : Céline Salsac Award Recipient : Roxane Crabé Award Recipient : Anaïs Virenque Award Recipient : Claire Soulard Award Recipient : Margot Libralato Award Recipient : Stéphanie Venteo Award Recipient : Frédérique Scamps Award Recipient : Javier Hernandez Award Recipient : Thierry Vincent Award Recipient : Cédric Raoul
                Funded by: AFM-Téléthon (French Muscular Dystrophy Association) 501100004923
                Award ID: PhD fellowship
                Award Recipient : Emmanuelle Coque Award Recipient : Frédérique Scamps Award Recipient : Cédric Raoul
                Funded by: E-RARE
                Award ID: ANR-14-RARE- 0006
                Award Recipient : Emmanuelle Coque Award Recipient : Nicolas Degauque Award Recipient : Marion Cadoux Award Recipient : Frédérique Scamps Award Recipient : David-Axel Laplaud Award Recipient : Thierry Vincent Award Recipient : Cédric Raoul
                Funded by: Agence Nationale de la Recherche (ANR) 501100001665
                Award ID: GliALS
                Award Recipient : Céline Salsac Award Recipient : Nicolas Degauque Award Recipient : Marion Cadoux Award Recipient : David-Axel Laplaud Award Recipient : Cédric Raoul
                Funded by: Association pour la Recherche sur la Sclérose Latérale Amyotrophique et autres Maladies du Motoneurone (ARSLA) 501100006510
                Award ID: CD8-ALS
                Award Recipient : Emmanuelle Coque Award Recipient : Roxane Crabé Award Recipient : Anaïs Virenque Award Recipient : Claire Soulard Award Recipient : Margot Libralato Award Recipient : Frédérique Scamps Award Recipient : Cédric Raoul
                Funded by: Agence Nationale de la Recherche (ANR) 501100001665
                Award ID: ANR-10-IBHU-005
                Award Recipient : Céline Salsac Award Recipient : Nicolas Degauque Award Recipient : Marion Cadoux Award Recipient : David-Axel Laplaud Award Recipient : Cédric Raoul
                Funded by: Pays de la Loire
                Award ID: IHU-Cesti project
                Award Recipient : Emmanuelle Coque Award Recipient : Nicolas Degauque Award Recipient : Marion Cadoux Award Recipient : Frédérique Scamps Award Recipient : David-Axel Laplaud Award Recipient : Thierry Vincent Award Recipient : Cédric Raoul
                Funded by: Nantes Metrople
                Award ID: IHU-Cesti project
                Award Recipient : Emmanuelle Coque Award Recipient : Nicolas Degauque Award Recipient : Marion Cadoux Award Recipient : Frédérique Scamps Award Recipient : David-Axel Laplaud Award Recipient : Thierry Vincent Award Recipient : Cédric Raoul
                Categories
                Biological Sciences
                Neuroscience

                amyotrophic lateral sclerosis,neuroimmunity,cytotoxic t lymphocytes,motoneuron,major histocompatibility complex i

                Comments

                Comment on this article